Companies: 10,795·Total market cap: $144.5T
Interpace Biosciences, Inc.

Interpace Biosciences, Inc.

IDXGOTCHealthcare● Active
$1.68
+$0.01(+0.60%)
Market Cap$46537519
P/E Ratio
52W High$2.4
52W Low$0.697
Overview

Interpace Biosciences, Inc. (IDXG) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · IDXG · as of Jun 9, 2026

Key Statistics

EPS (TTM)idxg eps ttm · idxg earnings per shareEarnings history
PE Ratio (TTM)idxg pe ratio ttm · idxg price to earningsPE Ratio deep dive
Revenue (TTM)idxg revenue ttm · idxg annual revenueFull revenue history
Dividend YieldNo Dividenddoes idxg pay dividends · idxg dividend yieldDividend history
Shares Outstandingidxg shares outstanding · idxg floatShares outstanding history
Next EarningsTBAidxg earnings date · idxg next earningsEarnings history

About Interpace Biosciences, Inc.

CEOThomas W. Burnell
IPO DateMay 20, 1998
Employees111
CountryUS

Interpace Biosciences, Inc. is a U.S.-based company specializing in advanced molecular diagnostic tests, bioinformatics, and pathology services, primarily focused on assessing cancer risk. Among its k…

what is interpace biosciences, inc. · idxg stock overview · interpace biosciences, inc. company profile · who is interpace biosciences, inc. ceo · idxg OTC · interpace biosciences, inc. headquarters · interpace biosciences, inc. business segments

About Stock Overview & Key Data

Interpace Biosciences, Inc. (IDXG) is a Healthcare company in the Medical - Diagnostics & Research industry, listed on OTC since May 20, 1998. As of the latest trading session, IDXG stock price is $1.68, with a market capitalization of $46.5M. The stock has returned — over the past 12 months and — year-to-date.

Frequently Asked Questions

As of the latest trading session, Interpace Biosciences, Inc. (IDXG) stock price is $1.68. The stock is traded on OTC under the ticker symbol IDXG. The 52-week range is $0.70 – $2.40.

IDXG stock priceIDXG quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice